Citations

Clear

371 citation(s) found for "Cho, B".

The Current Diagnostic Performance of MRI-Based Radiomics for Glioma Grading: A Meta-Analysis
Skogen, Karoline , Zeppieri, Marco , Ugga, Lorenzo , Brinjikji, Waleed , Maria, Lucio De , Ponzio, Francesco , Cho, Hwan-ho , Tsougos, Ioannis , Gasparini, Mauro , Ius, Tamara , Panciani, Pier Paolo , Fontanella, Marco Maria , Agosti, Edoardo

Mayo Clinic

Journal of Integrative Neuroscience | May 17, 2024 | Volume: 23 | Issue: 5 | Pages: No page available

10.31083/j.jin2305100 | PMID 38812383 Get It

Background: Multiple radiomics models have been proposed for grading glioma using different algorithms, features, and sequences of magnetic resonance imaging. The research seeks to assess the present overall performance of radiomics for grading glioma. Methods: A systematic literature review of the databases Ovid MEDLINE PubMed, and Ovid EMBASE for publications published on radiomics for glioma grading between 2012 and 2023 was performed. The systematic review was carried out following the criteria of Preferred Reporting Items for Systematic Reviews and Meta-Analysis. Results: In the meta-analysis, a total of 7654 patients from 40 articles, were assessed. R-package mada was used for modeling the joint estimates of specificity (SPE) and sensitivity (SEN). Pooled event rates across studies were performed with a random-effects meta-analysis. The heterogeneity of SPE and SEN were based on the χ2 test. Overall values for SPE and SEN in the differentiation between high-grade gliomas (HGGs) and low-grade gliomas (LGGs) were 84% and 91%, respectively. With regards to the discrimination between World Health Organization (WHO) grade 4 and WHO grade 3, the overall SPE was 81% and the SEN was 89%. The modern non-linear classifiers showed a better trend, whereas textural features tend to be the best-performing (29%) and the most used. Conclusions: Our findings confirm that present radiomics’ diagnostic performance for glioma grading is superior in terms of SEN and SPE for the HGGs vs. LGGs discrimination task when compared to the WHO grade 4 vs. 3 task.
Airway Mucus Plugging and Cause-specific Mortality in COPD
Mettler, S.K., Nath, P. H., Yen, A.A., Kligerman, Seth , Jacobs, Kathleen, Manapragada, Padma P. , Abozeed, Mostafa , Zahid, Mohd , Ahmed, Asmaa , Terry, Nina , Elalami, Rim, Sonavane, Sushilkumar K. , Billatos, Ehab , Wang, Wei , Cho, M.H. , Grumley, Scott , Kim, Katherine Callaway , Nardelli, Pietro , Aziz, Muhammad Usman , Estépar, Raúl San Jośe , Abdalla, M., Díaz, Alejandro A.

Mayo Clinic

C24. CLINICAL, BIOLOGIC, AND RADIOLOGIC MARKERS OF KEY OUTCOMES AND TREATMENT RESPONSE IN COPD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A5122-A5122

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5122 Get It

Socioeconomic Deprivation Is Associated With Prevalence and Persistence of Airway Mucus Plugs in Patients With COPD
Mettler, S.K., Nath, P. H., Yen, A.A., Kligerman, Seth , Jacobs, Kathleen, Manapragada, Padma P. , Abozeed, Mostafa , Zahid, Mohd , Ahmed, Asmaa , Terry, Nina , Sonavane, Sushilkumar K. , Billatos, Ehab , Wang, Wei , Cho, M.H. , Grumley, Scott , Kim, Katherine Callaway , Nardelli, Pietro , Aziz, Muhammad Usman , Estépar, R. San José , Abdalla, Mazen A. , Díaz, Alejandro A.

Mayo Clinic

A54. EXPLORING ASTHMA AND COPD: DIVERSE INSIGHTS FROM GLOBAL PERSPECTIVES | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A2110-A2110

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2110 Get It

Airway Mucus Plugging in Upper Versus Lower Lobes and Associations With Outcomes in COPD
Mettler, S.K., Nath, P. H., Yen, A.A., Kligerman, Seth , Jacobs, Kathleen, Manapragada, Padma P. , Abozeed, Mostafa , Zahid, Mohd , Ahmed, Asmaa , Terry, Nina , Elalami, Rim, Sonavane, Sushilkumar K. , Billatos, Ehab , Wang, Wei , Cho, M.H. , Grumley, Scott , Kim, Katherine Callaway , Nardelli, Pietro , Aziz, Muhammad Usman , Estépar, Raúl San Jośe , Abdalla, Mazen A. , Díaz, Alejandro A.

Mayo Clinic

A29. WHAT IS YOUR DAMAGE? IMAGING-BASED PHENOTYPES OF COPD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1247-A1247

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1247 Get It

Evolution of distal limb perfusion management in adult peripheral venoarterial extracorporeal membrane oxygenation with femoral artery cannulation
Simons, Jorik , Fraser, John F. , Zaaqoq, Akram , Cho, Sung‐Min , Patel, B. M. , Brodie, Daniel , Jung, Jae Seung , Salazar, Leonardo, Meani, Paolo , Mariani, Silvia , Yannopoulos, Demetris , Broman, Lars Mikael , Chen, Yih‐Sharng , Riera, Jordi , Mook, Walther van , Zaaqoq, Akram M , Cho, Sung-Min , Meani, Paolo , Chen, Yih-Sharng , Riera, Jordi , Lorusso, Roberto , Mees, Barend M.E. , MacLaren, Graeme , Bělohlávek, Jan , Belliato, Mirko , Mauro, Michele Di , Lorusso, Roberto

Mayo Clinic

Perfusion | April 23, 2024 | Volume: 39 | Issue: 1_suppl | Pages: 23S-38S

10.1177/02676591241236650 | PMID 38651584 Get It

Limb ischaemia is a clinically relevant complication of venoarterial extracorporeal membrane oxygenation (VA ECMO) with femoral artery cannulation. No selective distal perfusion or other advanced techniques were used in the past to maintain adequate distal limb perfusion. A more recent trend is the shift from the reactive or emergency management to the pro-active or prophylactic placement of a distal perfusion cannula to avoid or reduce limb ischaemia-related complications. Multiple alternative cannulation techniques to the distal perfusion cannula have been developed to maintain distal limb perfusion, including end-to-side grafting, external or endovascular femoro-femoral bypass, retrograde limb perfusion (e.g., via the posterior tibial, dorsalis pedis or anterior tibial artery), and, more recently, use of a bidirectional cannula. Venous congestion has also been recognized as a potential contributing factor to limb ischaemia development and specific techniques have been described with facilitated venous drainage or bilateral cannulation being the most recent, to reduce or avoid venous stasis as a contributor to impaired limb perfusion. Advances in monitoring techniques, such as near-infrared spectroscopy and duplex ultrasound analysis, have been applied to improve decision-making regarding both the monitoring and management of limb ischaemia. This narrative review describes the evolution of techniques used for distal limb perfusion during peripheral VA ECMO.
1012 Concordance and Test-Retest Consistency of Sleep Biomarker Based Phenotyping of Neurodegenerative Disorders
Levendowski, Daniel J. , Walsh, Christine M. , Cho, Yeilim, Lee‐Iannotti, Joyce , Mazeika, Gandis, Yack, Leslie M. , Tsuang, Debby W. , Berka, Chris , Mazeika, Gandis, Boeve, Bradley F. , Neylan, Thomas C. , Louis, Erik K. St.

Mayo Clinic

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A435-A435

10.1093/sleep/zsae067.01012 Get It

Abstract Introduction In this pilot study, the diagnostic agreement for sleep biomarker-based neurodegenerative disorder (NDD) risk probabilities was evaluated in patients with Alzheimer’s disease dementia (AD), Lewy Body disease (LBD), and isolated REM sleep behavior disorder (iRBD) and controls with a Mini-Mental State Exam scores>28. Methods Sleep biomarkers recorded with the Sleep Profiler (Advanced Brain Monitoring, Inc) were used as inputs to a 4-class machine learning algorithm trained to assign NDD risk probabilities to AD=27, LBD=19, iRBD=15 and controls (CG=58). Input variables included age, time-REM, non-REM hypertonia, autonomic-activation index, spindle-duration, atypical-N3, time-supine, sleep-efficiency, relative-theta, and theta/alpha. Records with CG output probabilities >70% were labeled Probably-normal, and from 45-70% Likely-normal with indications of a NDD added when the LBD, AD or prodromal synucleinopathy (pSYN) risks exceeded approximately 25%. Similar thresholds were used to assign Likely- or Probable- LBD, AD, or pSYN based each of the group probabilities. Classification accuracies were evaluated in AD=37, LBD=19, iRBD=19 and CG=61 records. Longitudinal test-retest reliabilities were assessed for CG (n=45, range 8-56 months), and after six-months for LBD (n=10) and AD (n=9). Results In the AD group, NDD risk assignments were consistent with diagnoses=85%, with Probable-NDD=59%, Likely-NDD=11%, Normal plus AD/Mixed indications=15%, but with 5%=Probably-normal. In the LBD group, assigned risks were consistent with the diagnosis=79%, with Probable-NDD=74%, Normal with pSYN indications=5%, but with 11%=Probably-normal. In the iRBD group, Probable-NDD=42%, Normal plus pSYN indications=26% and Probably-normal=32%. In the CG group, 89% were assigned minimal NDD risks with Probably-normal=67%, Normal plus indications=22%, but with Likely NDD=8% and Probable NDD=3%. The AD test-retest reliability showed the same NDD classifications=78%, with slightly increasing=11% and decreased=11%. In the LBD group, the same NDD classifications were achieved=80%, with trending equivalence=10%, and decreasing severity=20%. The CG test-retest reliability showed the same NDD classifications=76%, with trending equivalence=22%, and increased severity=2%. Conclusion Consistencies between the diagnoses and assigned NDD risks and test-retest classification agreements were approximately 80% in the AD, LBD, and CG groups. In the iRBD group, the NDD risks were disbursed consistent with the range of expected severities. These results needed to be cross-validated in independent NDD datasets. Support (if any) NIH grants R44AG050326, R44AG054256, RO1AG060477, R33AG064271, ULRR024150, R34AG056639.
0753 Relationship Between OSA and Sleep Biomarker Based Neurodegenerative Disorder Risk in a Clinical Cohort
Mazeika, Gandis, Cho, Yeilim, Anderson, Jack , Levendowski, Daniel J. , Walsh, Christine M. , Lee‐Iannotti, Joyce , Mazeika, Gandis, Tsuang, Debby W. , Neylan, Thomas C. , Lewis, Simon J.G. , Louis, Erik K. St.

Mayo Clinic

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A322-A323

10.1093/sleep/zsae067.0753 Get It

Abstract Introduction In this pilot study, sleep biomarker-based neurodegenerative disorder (NDD) risk was assessed in a clinical cohort of patients diagnosed with varying severity of obstructive sleep apnea (OSA). Methods Consecutive in-home multi-night Sleep Profiler records from a community sleep clinic were screened for age >54 years old. Cases with comorbid restless leg syndrome, hypersomnia, missing apnea-hypopnea indexes (AHI), AHI< 5 or single-night recordings were excluded. The 67 remaining records were 40% female, ages 63 + 7.4 years and up to 84 years old. NDD risk was assigned using a machine-learning algorithm combining age and nine sleep biomarkers to assign group probabilities: for Alzheimer’s disease, Lewy Body disease, prodromal synucleinopathy and controls (CG). Sleep biomarkers included: time-REM, non-REM hypertonia, autonomic-activation index, spindle-duration, atypical-N3, time-supine, sleep-efficiency, relative-theta, and theta/alpha. Those with CG probability score >70% were classified as “Probably-normal”. Those with CG probability between 45 - 70% were classified as “Likely-normal”. Insomnia severity >14 and a PHQ 9 > 5 were used as cutoffs for clinical insomnia and depression. Mann-Whitney U-tests were used to evaluate group differences. Results This cohort had 37% mild, 34% moderate, and 29% severe OSA. Self-reported comorbid insomnia and depression were present in 43%. Seventy-three percent of patients were classified as “Probably-normal”, 16% “Likely-normal”, 11% “Likely-NDD” or “Probable-NDD”. The “Probably-normal” group was younger than the rest of the cohort (62 + 6.2 years vs. 68 + 8.6 years, p< 0.01). Of those classified as “Probably-normal” (n=49), OSA was mild in 16, moderate in 17 and severe in 16. Mean AHI trended higher in the “Probably-normal” group than in those with elevated NDD risk (29 + 23.9 vs. 19 + 13.6 events/h, p=0.085). Conclusion Approximately 89% of the clinical cohort was classified as “Probably-normal” or “Likely-normal”. NDD risk was age-dependent. Interactions between OSA severity and NDD risk were not apparent in these findings, possibly related to group-wide effects. NDD risk, as measured by this model, did not appear to be adversely biased by untreated OSA. These results suggest a need for longitudinal studies to compare NDD risk in untreated OSA versus controls without sleep disordered breathing. Support (if any) NIH grants R44AG050326, R44AG054256, RO1AG060477, R33AG064271, ULRR024150, and R34AG056639.
Abstract CT243: Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL)
Novelli, Silvana , Poon, Michelle, Guidez, Stéphanie , Jagadeesh, Deepa , Mayer, L, Tani, Monica , Cai, Jingxian, Uppala, Amulya , Shariff, Saleem, Brouwer‐Visser, Jurriaan , Chaudhry, Aafia, Ambati, Srikanth, Mussetti, Alberto , Mussetti, Alberto , Chong, Geoffrey , Taszner, Michał , Cho, Seok‐Goo , Villasboas, José C. , Ubieto, Ana Jiménez , Tessoulin, Benoit , Tucker, David , Walewski, Jan , Song, Yuqin , Bachy, Emmanuel , Alonso, Aránzazu , Luminari, Stefano , Iskierka‐Jazdzewska, Elżbieta , Mohamed, Hesham , Kim, Tae Min

Mayo Clinic

Cancer Research | April 5, 2024 | Volume: 84 | Issue: 7_Supplement | Pages: CT243-CT243

10.1158/1538-7445.am2024-ct243 Get It

Abstract Background: R/R FL is an incurable disease and outcomes worsen with successive relapses. A high unmet need remains for therapies that improve tumor control and extend survival after relapse. Odronextamab, an off-the-shelf CD20×CD3 bispecific antibody, demonstrated compelling efficacy, generally manageable safety, and maintenance of pt-reported overall quality of life scores from baseline in an interim analysis of the ELM-2 study (NCT03888105) in heavily pretreated pts with R/R FL (Villasboas et al. ASH 2023). Here, for the first time, we present the primary analysis of R/R FL in ELM-2. Methods: IV odronextamab was administered in 21-day cycles (C) until disease progression/unacceptable toxicity. Steroid prophylaxis and step-up dosing (0.7/4/20 mg) were used in C1 to mitigate the risk of cytokine release syndrome (CRS), followed by 80 mg on Days (D) 1, 8, and 15 of C2-4. Maintenance dosing continued at 160 mg Q2W, or Q4W if complete response (CR) was durable for 9 months (mo). Primary endpoint was objective response rate (ORR) per Lugano criteria by independent central review (ICR). Secondary endpoints included CR rate, duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Primary analysis was performed when 128 pts had ≥52 weeks’ follow-up. Results: At data cutoff (Oct 20, 2023), 128 pts with FL Grade (Gr) 1-3a were evaluable for efficacy and safety: median age 61 yrs (range 22-84); FLIPI risk score 3-5 57.8%; POD24 49.2%; median 3 prior lines of therapy (2-13); 71.9% refractory to last treatment (Tx); 74.2% refractory to an anti-CD20 antibody. The median no. of Tx cycles was 19.4 (0.1-95.9); 95.3% and 85.2% of pts completed C1 and C4, respectively.Median efficacy follow-up was 20.1 mo; ORR was 80.5% and CR rate was 73.4% confirmed by ICR. Responses were durable (median DOR 22.6 mo; median DOCR 25.1 mo). Median PFS was 20.7 mo and 24-mo PFS was 46.1%. Median OS was not reached and 24-mo OS was 70.1%.The odronextamab safety profile was generally manageable and consistent with previous reports. Tx-emergent adverse events (AEs) occurred in all pts (Gr ≥3 85.9%); 15.6% had AEs leading to Tx discontinuation. With 0.7/4/20 mg step up (n=60), CRS events were mostly low grade (Gr 1 45.0%; Gr 2 10.0%; Gr 3 in 1 pt), occurred mostly in C1, and resolved in a median of 2 days; ICANS was reported in 1 pt (Gr 2). Infection rates were consistent with heavily pretreated, immunosuppressed pts (Leonard et al. JCO 2019; Hayne et al. BBMT 2020), occurring in 79.7% (102/128) of pts (Gr 4/5 14.0%; COVID-19 36.7% [Gr 5 6.3%]).Conclusion: Odronextamab demonstrated deep and durable responses in heavily pretreated pts with R/R FL; 91% of responders achieved CR, correlating with favorable PFS and OS at 24 mo. Odronextamab had a generally manageable safety profile and a low incidence of Gr 3 CRS/ICANS. Odronextamab could offer an important off-the-shelf Tx option for pts with heavily pretreated R/R FL. Citation Format: Geoffrey Chong, Michal Taszner, Silvana Novelli, Seok-Goo Cho, Jose C. Villasboas, Ana Jiménez Ubieto, Benoît Tessoulin, Michelle Poon, David Tucker, Jan Walewski, Yuqin Song, Emmanuel Bachy, Stephanie Guidez, Aranzazu Alonso, Deepa Jagadeesh, Stefano Luminari, Laura Magnano Mayer, Elżbieta Iskierka-Jażdżewska, Monica Tani, Jingxian Cai, Amulya Uppala, Saleem Shariff, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Tae Min Kim. Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT243.
Understanding the different effects of fouling mechanisms on working and reference electrodes in fast-scan cyclic voltammetry for neurotransmitter detection
Jang, J. , Cho, Hyun‐U , Hwang, Sangmun, Kwak, Youngjong , Kwon, Haeun , Heien, Michael L. , Bennet, Kevin E. , Shin, Hojin , Lee, Kendall H. , Jang, Dong Pyo , Jang, Jaehyun , Jang, Dong Pyo , Oh, Yoonbae

Mayo Clinic

The Analyst | April 4, 2024 | Volume: 149 | Issue: 10 | Pages: 3008-3016

10.1039/d3an02205f | PMID 38606455 Get It

The distinct impacts of fouling mechanisms on a carbon fiber microelectrode and an Ag/AgCl reference electrode, affecting their performance in neurotransmitter detection via Fast-scan Cyclic Voltammetry.
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231
Hayashi, Robert J. , Hermiston, Michelle L. , Wood, Brent L. , Teachey, David T. , Devidas, Meenakshi , Chen, Zhiguo , Annett, Robert D. , Asselin, Barbara L. , August, Keith J. , Cho, Steve , Galardy, Paul J. , Harker‐Murray, Paul , Jaju, Alok , Lam, Allison, Miles, Rodney R., Okada, Maki , Patel, Samir , Schechter, Tal , Shimano, Kristin A. , Singh, Neelam, Steele, Amii C., Sulis, Maria Luisa , Vargas, Sarah , Winter, Stuart S. , Wood, Charlotte, Loh, Mignon L. , Raetz, Elizabeth A. , Bollard, Catherine M. , Allen, Carl E. , August, Keith , Freedman, Jason Lawrence , Galardy, Paul J , Harker-Murray, Paul , Horton, Terzah M. , Jaju, Alok I , Messinger, Yoav H , Okada, Maki , Schafer, Eric S , Shimano, Kristin A , Sulis, Maria L , Winter, Stuart S , Zweidler-McKay, Patrick A , Loh, Mignon L , Hunger, Stephen P , Raetz, Elizabeth A , Bollard, Catherine M , Allen, Carl E , Wood, Brent L , Devidas, Meenakshi , Dunsmore, Kimberly P , Messinger, Yoav H. , Schafer, Eric S. , Hunger, Stephen P.

Mayo Clinic

Blood | March 8, 2024 | Volume: 143 | Issue: 20 | Pages: 2053-2058

10.1182/blood.2023021184 | PMID 38457359 Get It

Abstract Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains a challenge. AALL1231 was a Children’s Oncology Group phase 3 clinical trial for newly diagnosed patients with T acute lymphoblastic leukemia or T-LL, randomizing children and young adults to a modified augmented Berlin-Frankfurt-Münster backbone to receive standard therapy (arm A) or with addition of bortezomib (arm B). Optional bone marrow samples to assess minimal residual disease (MRD) at the end of induction (EOI) were collected in T-LL analyzed to assess the correlation of MRD at the EOI to event-free survival (EFS). Eighty-six (41%) of the 209 patients with T-LL accrued to this trial submitted samples for MRD assessment. Patients with MRD <0.1% (n = 75) at EOI had a superior 4-year EFS vs those with MRD ≥0.1% (n = 11) (89.0% ± 4.4% vs 63.6% ± 17.2%; P = .025). Overall survival did not significantly differ between the 2 groups. Cox regression for EFS using arm A as a reference demonstrated that MRD EOI ≥0.1% was associated with a greater risk of inferior outcome (hazard ratio, 3.73; 95% confidence interval, 1.12-12.40; P = .032), which was independent of treatment arm assignment. Consideration to incorporate MRD at EOI into future trials will help establish its value in defining risk groups. CT# NCT02112916.